14 completed. 14 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 14 |
| Phase 2 | 2 | Completed 2 |
Follow Communication Disorders: new trials by email Literature Review of Communication Disorders trials Research Report on Communication Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care - Mild Cognitive Impairment, Dementia, Mild | Phase 3 | Completed | Alzheimer's Prevention and Reversal Project, Inc. | 73 | 2023-07-31 | 2026-02-18 |
| Brain Correlates of Multimodal Rehabilitation in Chronic Post-stroke Aphasia Donepezil, Intensive-Language Action Therapy, Transcranial direct current stimulation - Aphasia, Stroke | Phase 3 | Completed | University of Malaga | 20 | 2019-01-08 | 2020-11-05 |
| Use of Local Intraoperative Steroid in MIS TLIF Methylprednisolone, Dexamethasone - Dysphasia | Phase 3 | Completed | Rush University Medical Center | 105 | 2015-11-13 | 2020-11-20 |
| AM-111 in the Treatment of Acute Inner Ear Hearing Loss Placebo, AM-111 0.4 mg/ml, AM-111 0.8 mg/ml - Hearing Loss | Phase 3 | Completed | Auris Medical AG | 256 | 2015-11-01 | 2023-09-14 |
| Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease Flutemetamol (18F) Injection - Mild Cognitive Impairment, Alzheimer's Disease | Phase 3 | Completed | GE Healthcare | 365 | 2009-12-01 | 2014-09-11 |
| A Study to Assess the Efficacy and Safety of Pagoclone for Adults With Stuttering pagoclone, placebo - Stuttering | Phase 2 / Phase 3 | Completed | Endo USA Inc., a Keenova Therapeutics Company | 321 | 2009-02-01 | 2012-08-28 |
| Melodic-Intonation-Therapy and Speech-Repetition-Therapy for Patients With Non-fluent Aphasia Melodic Intonation Therapy, Speech-Repetition-Therapy - Aphasia, Stroke | Phase 3 | Completed | Beth Israel Deaconess Medical Center | 30 | 2008-02-01 | 2020-09-21 |
| Controlled Trial to Test the Efficacy of Lipid-based Nutrient Supplements to Prevent Severe Stunting Among Infants Milk-containing fortified spread, Soy-containing fortified spread, Maize-soy flour - Malnutrition, Stunting | Phase 3 | Completed | Tampere University | 840 | 2008-01-01 | 2014-05-21 |
| Augmenting Language Therapy for Aphasia: Levodopa levodopa/carbidopa, Placebo comparator - Nonfluent Aphasia, Stroke | Phase 2 / Phase 3 | Completed | Shirley Ryan AbilityLab | 36 | 2007-10-01 | 2013-12-25 |
| Effects of OroPharyngeal Exercises on Patients With Moderate Obstructive Sleep Apnea Deep breathing, bilateral alternate chewing, nasal lavage, Oropharyngeal exercises - Obstructive Sleep Apnea | Phase 3 | Completed | University of Sao Paulo | 30 | 2004-02-01 | 2008-04-17 |
| A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children risperidone - Learning Disorders, Child Behavior Disorders | Phase 3 | Completed | Janssen-Cilag Ltd. | 19 | 2003-09-01 | 2011-05-20 |
| A Comparison of Language Intervention Programs Fast ForWord, Computer Assisted Language Intervention, Individual Language Intervention - Language Disorders | Phase 3 | Completed | National Institute on Deafness and Other Communication Disorders (NIDCD) | 216 | 2002-06-01 | 2006-04-24 |
| Treatment of Childhood Social Phobia Social Effectiveness Therapy for Children (SET-C), Fluoxetine, Pill Placebo - Social Phobia | Phase 3 | Completed | University of Central Florida | 139 | 2001-04-01 | 2013-08-01 |
| Reading Problems in Children Living in Urban Areas Reading Instruction - Dyslexia | Phase 3 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1400 | 1993-07-01 | 2015-06-03 |
Aphasia (4) · Stroke (4) · Alzheimer Disease (2) · Cognitive Dysfunction (2) · Learning Disabilities (2) · Speech Disorders (2) · Anomia (1) · Aphasia, Broca (1) · Brain Infarction (1) · Brain Ischemia (1) · Cerebral Infarction (1) · Cerebrovascular Disorders (1) · Child Behavior Disorders (1) · Deafness (1)
Nervous System Diseases (14) · Neurobehavioral Manifestations (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Signs and Symptoms (13) · Language Disorders (9) · Mental Disorders (7) · Neurodevelopmental Disorders (7) · Brain Diseases (5) · Central Nervous System Diseases (5) · Speech Disorders (5) · Cardiovascular Diseases (4) · Vascular Diseases (4) · Cerebrovascular Disorders (3)
D-JNKI-1 (1) · Dexamethasone (1) · Donepezil (1) · Exercise (1) · Fluoxetine (1) · Hormones (1) · Methylprednisolone (1) · Nasal Lavage (1) · Risperidone (1) · Standard of Care (1) · Transcranial Direct Current Stimulation (1) · carbidopa, levodopa drug combination (1) · flutemetamol (1) · pagoclone (1)
Alzheimer's Prevention and Reversal Project, Inc. (1) · Auris Medical AG (1) · Beth Israel Deaconess Medical Center (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · GE Healthcare (1) · Janssen-Cilag Ltd. (1) · National Institute on Deafness and Other Communication Disorders (NIDCD) (1) · Rush University Medical Center (1) · Shirley Ryan AbilityLab (1) · Tampere University (1) · University of Central Florida (1) · University of Malaga (1) · University of Sao Paulo (1)
United States (7) · Brazil (1) · Bulgaria (1) · Malawi (1) · Spain (1)
Andrea Norton, BM (1) · Barbara R. Foorman (1) · Dale Bredesen, MD (1) · Geraldo Lorenzi-Filho, MD, PhD (1) · Gottfried Schlaug, MD, PhD (1) · Kat Toups, MD (1) · Kenneth Maleta, MBBS, PhD (1) · Kern Singh, MD (1) · Marcelo L Berthier, MD, PhD (1) · Paul Sherwin, M.D. (1) · Per Ashorn, MD, PhD (1) · Ronald Gillam, PhD (1)
PMID 18030084, PMID 19234106, PMID 19673813, PMID 20013046, PMID 21197418, PMID 21391024, PMID 22228076, PMID 25332483, PMID 27403608, PMID 27798342, PMID 30497132, PMID 35351181, PMID 35433325
R01DC008796 (1), R01HD030995 (1), R01MH053703 (1)